Heparin and heparan sulfate binding chimeric vectors

Details Heparin and heparan sulfate binding chimeric vectors Heparin and heparan sulfate binding chimeric vectors

2011-01-11

2011-01-11

Leavitt, Maria (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S320100, C435S252300, C435S325000, C435S455000, C435S456000, C435S471000, C536S023100

Reexamination Certificate

active

07867484

ABSTRACT:
The present invention is based on the finding that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. In some embodiments, a substitution of a single amino acid that is unique to the AAV6 capsid (Lys-531) among other AAVs that have been characterized to date can confer one or more desirable properties to other AAVs.

REFERENCES:
patent: 6410300 (2002-06-01), Samulski et al.
patent: 6491907 (2002-12-01), Rabinowitz et al.
patent: 6703237 (2004-03-01), Samulski et al.
patent: 7172893 (2007-02-01), Rabinowitz et al.
patent: 2003/0022870 (2003-01-01), Dzau et al.
patent: 2006/0188483 (2006-08-01), Rabinowitz et al.
patent: 2006/0188484 (2006-08-01), Rabinowitz et al.
patent: WO 00/28004 (2000-05-01), None
patent: WO 2005/106046 (2005-11-01), None
Rutledge et al. J. Virol. 72;309-319; 1998.
International Search Report and Written Opinion of International Application No. PCT/US07/02251, mailed Sep. 18, 2008 (13 pages).
Opie et al. “Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate Proteoglycan Binding”Journal of Virology77(12):6995-7006 (2003).
Wu et al. “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism”Journal of Virology74(18):8635-8647 (2000).
Grimm et al. “Helper Virus-Free, Optically Controllable, and Two-Plasmid-Based Production of Adeno-associated Virus Vectors of Serotypes 1 to 6”Molecular Therapy7(6): 839-850 (Jun. 2003).
Grimm et al. “Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy”Blood102(7): 2412-2419 (Oct. 1, 2003).
Halbert et al. “Adeno-Associated Virus Type 6 (AAV6) Vectors Mediate Efficient Transduction of Airway Epithethial Cells in Mouse Lungs Compared to That of AAV2 Vectors”Journal of Virology75(14): 6615-6624 (Jul. 2001).
Jooss et al. “Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers”Journal of Virology72(5): 4212-4223 (May 1998).
Kern et al. “Identification of a Heparin-Binding Motif on Adeno-Associated Virus Type 2 Capsids”Journal of Virology77(20): 11072-11081 (Oct. 2003).
Vandenberghe et al. “Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid”Nature Medicine: 1-5 (Jul. 16, 2006).

Affiliated with

Also associated with

Rating

Heparin and heparan sulfate binding chimeric vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heparin and heparan sulfate binding chimeric vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparin and heparan sulfate binding chimeric vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2660411